Medpace (MEDP)
Health Care · contract research organization (CRO) · NASDAQ
Medpace is a mid-sized, scientifically-focused global CRO that provides full-service clinical trial management for drug and medical device development.
What Medpace does
Medpace is a global clinical contract research organization (CRO) providing scientifically-driven, outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company manages the entire clinical trial process, offering services such as clinical development planning, regulatory affairs, clinical monitoring, data management, and biostatistics.
Themes: drug development outsourcing, clinical research services, biotech R&D services, medical device clinical trials
Fundamentals
- Price$620.75 as of 2026-08-21 close
- Market cap$17.3B as of 2026-08-21
- 1-year return+36.9% 2025-08-21 close $453.34 → 2026-08-21 close $620.75
- P/E33.13 as of 2026-08-24
- Net margin+17.7% as of 2026-08-24
- Gross margin+28.8% as of 2026-08-24
- ROE+110.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+24.7% as of 2026-08-24
- Revenue CAGR (3y)+20.1% SEC XBRL
- Beta1.19 as of 2026-08-24
- Last reported earnings2026-07-22 SEC EDGAR Form 8-K (Item 2.02)
How MEDP compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MEDP is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
60.3 #196 of 1,704 scored · #46 of 240 in Health Care
Trend 77th: a strong uptrend, with buyers in control; volume and participation 65th: it gapped 22.5% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is setup 45th: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 0% of it.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Medpace looks technically
Medpace (MEDP) is trading 18.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 10 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range.
Trend
7
| Distance from the 200-day | it is trading 18.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +18.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $548.67 | $548.67 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $522.89 | $522.89 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 10 trading days ago — a "golden cross", a bullish long-term signal | 10 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with buyers in control | 39.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30) | 66.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($563.45 to $629.69) — its "stochastic" reading is 87 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 86.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $677.90 | $677.90 |
|---|---|---|
| From the 52-week high | it is 8.4% below its 52-week high (its highest price of the past year) | -8.4% |
| Above the 52-week low | it is 66.4% above its 52-week low (its lowest price of the past year) | +66.4% |
| Below the 52-week high | it is 8.4% below its highest point of the past year | 8.4% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $677.90 (set on 2026-07-23) | $677.90 |
| Given back of the 52-week move | over the past year its closes ranged ($393.42 to $620.75), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $472.99 to $480.26. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 8.4% below its all-time high | -8.4% |
| Nearest price level | it is trading 1.0% below a resistance level at $626.72 — a price it turned at three times since 2025-10-23, most recently on 2026-01-16. Since 2024-08-21 it has 17 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.0% |
| All-time low | its lowest closing price on record is $21.76 (set on 2017-05-03) | $21.76 |
| Above the all-time low | it is 2752.7% above its all-time low | +2,753% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 87% of it) | 13th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $20.86 between its high and its low — about 3.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $20.86 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $563.13 and $617.56 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $563.13 – $590.35 – $617.56 |
| Typical daily range (% of price) | its price moves about 3.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.4% |
| Stretch from the 200-day average | it is trading 4.7 daily ranges above its 200-day average price (18.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.72× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 22.5% above the previous close 21 sessions ago and has not traded back through the level it left behind at 528.12 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +22.5% |
| Gap filled | a 2.1% gap down opened on 2026-07-08 has been "filled" 21 sessions ago — price traded back through the level the gap left behind, and it took 11 sessions to close | 21 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +5.16% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 14.4 percentage points (the stock gained 16.8% while the market gained 2.3%) | +14.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 41.2 percentage points (the stock gained 44.3% while the market gained 3.1%) | +41.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 25.7 percentage points (the stock gained 36.8% while the market gained 11.1%) | +25.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 16.4 percentage points (the stock gained 36.9% while the market gained 20.5%) | +16.4% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.4% of the share price. | +18.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 25% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $495.04 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +25.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-07-22 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $587.29 — a volume-weighted average of daily closes over 23 sessions, not a true tick-by-tick VWAP. | +5.7% |
Price levels it has turned at before
MEDP last closed at $620.75 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $626.72 | Resistance | 1.0% above the last close | turned there three times · 2025-10-23 to 2026-01-16 |
| $608.66 | Support | 1.9% below the last close | turned there twice · 2025-11-11 to 2026-08-11 |
| $565.68 | Support | 8.9% below the last close | turned there twice · 2026-07-06 to 2026-08-04 |
| $549.08 | Support | 11.6% below the last close | turned there twice · 2025-10-01 to 2026-01-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$581.83 range $370.00 – $692.00; median $604.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MEDP
- Consensus EPS estimate$4.44 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the continued outsourcing of R&D by biotechnology and pharmaceutical companies.","Potential for loss or delay of clinical trial contracts and failure to maintain high-quality clinical trial data standards.","Exposure to fluctuations in global regulatory environments and international currency exchange rates."]
What changed in the latest 10-Q
AI-assisted comparison of MEDP's 10-Q filed 2026-04-23 against the prior one filed 2025-10-23.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Reference to Annual Report on Form 10-K fiscal year changed from 'December 31, 2024' (filed 2025-10-23) to 'December 31, 2025' (filed 2026-04-23)
- Notes:
- Both text excerpts are truncated at the same point ('Risk Factors' in '). Full comparison limited to provided text.
Risk Factors
- Added:
- Newer filing (2026-04-23) contains financial statements as of March 31, 2026 and three months ended March 31, 2026, compared to older filing (2025-10-23) which contains statements as of September 30, 2025 and nine months ended September 30, 2025
- Newer filing shows Cash and cash equivalents of $652,681 thousand as of March 31, 2026 versus $285,351 thousand as of September 30, 2025
- Newer filing shows Total shareholders' equity of $598,314 thousand as of March 31, 2026 versus $293,641 thousand as of September 30, 2025
- Newer filing shows Net income of $123,870 thousand for three months ended March 31, 2026 versus $111,135 thousand for three months ended September 30, 2025
- Newer filing reports Accumulated deficit of $(336,111) thousand as of March 31, 2026 versus $(596,237) thousand as of September 30, 2025
- Removed:
- Older filing (2025-10-23) contained nine months ended September 30 comparative data which does not appear in newer filing (2026-04-23)
- Older filing contained full nine-month statements of operations, comprehensive income, cash flows, and shareholders' equity build-up; newer filing contains only three-month data
- Reworded:
- Item 1A Risk Factors page reference changed from page 27 in older filing to page 25 in newer filing
- Item 3 Defaults Upon Senior Securities page reference changed from page 28 in older filing to page 25 in newer filing
- Item 4 Mine Safety Disclosures page reference changed from page 28 in older filing to page 25 in newer filing
- Item 5 Other Information page reference changed from page 28 in older filing to page 25 in newer filing
- Item 6 Exhibits page reference changed from page 30 in older filing to page 25 in newer filing
- Exhibit Index page reference changed from page 31 in older filing to page 26 in newer filing
- Signatures page reference changed from page 32 in older filing to page 27 in newer filing
- Notes:
- The two filings report different reporting periods (Q1 2026 vs. Q3 2025), making period-to-period comparisons limited to structural and presentation differences
- The older filing provided nine-month year-to-date data while the newer filing only provides three-month quarterly data
- Text truncation in newer filing makes complete assessment of all sections impossible
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 6 sells ($23M) — 3 selling insiders
- Last 90 days0 buys · 7 sells ($31M) — 4 selling insiders
- Last 180 days0 buys · 7 sells ($31M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-11. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MEDP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 12 matched disclosures for MEDP from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding MEDP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 3,883,565
- Reported value $1,864,848,981
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MEDP had 1,746,898 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MEDP had 6.26% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.82 days to cover at the same settlement.
- Reported short interest (shares) 1,746,898
- Short interest (% of shares outstanding) 6.26%
- Prior settlement (shares) 2,190,722
- Reported change -20.26%
- Days to cover (reported) 3.82
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- IQVIA (IQV)
- Laboratory Corporation of America (LabCorp - LH)
- Parexel
- ICON plc (ICLR)
- Syneos Health
- PPD (Thermo Fisher Scientific - TMO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MEDP vs…
MEDP ranks in…
Frequently asked questions
What does Medpace (MEDP) do?
Medpace is a global clinical contract research organization (CRO) providing scientifically-driven, outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company manages the entire clinical trial process, offering services such as clinical development planning, regulatory affairs, clinical monitoring, data management, and biostatistics.
What sector is Medpace (MEDP) in?
Medpace (MEDP) is classified in the Health Care sector. Its industry is contract research organization (CRO). It trades on NASDAQ.
Who are Medpace's (MEDP) competitors?
Notable peers of Medpace (MEDP) include IQVIA, Laboratory Corporation of America (LabCorp - LH), Parexel, ICON plc and Syneos Health. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in MEDP?
Yes — we hold 12 matched STOCK Act disclosures for MEDP from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Medpace (MEDP) overbought or oversold right now?
Medpace (MEDP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 66, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MEDP come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.